E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Not possible to specify |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 23.0 |
E.1.2 | Level | HLT |
E.1.2 | Classification code | 10043905 |
E.1.2 | Term | Tobacco use |
E.1.2 | System Organ Class | 100000004869 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess efficacy of NFL-101 in reducing the positive reinforcing properties of cigarettes compared to placebo measured by the mCEQ "Smoking Satisfaction" (items 1, 2, and 12) subscale. |
|
E.2.2 | Secondary objectives of the trial |
To assess efficacy of NFL-101 in reducing the reinforcing properties of cigarettes compared to a placebo and safety after one administration of NFL-101. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• • Male or female subject ≥ 18 and ≤ 70-year-old at the time of consent; • Internet connection; • Subject currently smoking at least 10 cigarettes per day; • Exhaled CO ≥ 9 ppm; • Subject with a mCEQ Satisfaction subscale score ≥ 4 • Subject not wanting to stop smoking (MTSS score ≤ 2) • Subject not under tobacco cessation therapy since at least 30 days; • Considered as healthy for the study after a comprehensive clinical assessment (detailed medical history and complete physical examination); • For women of childbearing potential: commitment to consistently and correctly use of a highly effective contraceptive measure: combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable), intrauterine device (IUD), intrauterine hormone-releasing system (IUS), bilateral tubal occlusion, vasectomized partner or sexual abstinence for the duration of the trial; • Females of non-childbearing potential: either surgically sterilized or at least 1 year postmenopausal (amenorrhea duration at least 12 months); • Negative pregnancy test at screening visit; • Laboratory parameters within the normal range of the laboratory (hematological, blood chemistry tests). Individual values out of the normal range can be accepted if judged clinically non relevant by the investigator; • Negative prick test at screening visit for the whole study product (extract of Tobacco leaf and NaCL), and positive for histamine; • Covered by Health Insurance System and / or in compliance with the recommendations of National Law in force relating to biomedical research; • Subject having signed the informed consent agreement. |
|
E.4 | Principal exclusion criteria |
• Pregnancy and breastfeeding; • Concomitant participation to another clinical trial; • Concomitant active infectious diseases; • Subject who would receive more than 4500 euros as indemnities for his participation in biomedical research within the 12 last months, including the indemnities for the present study (for subjects in France only); • Subject who, in the judgment of the investigator, is likely to be non-compliant or uncooperative during the study, or unable to cooperate because of a language problem, poor mental development. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint is the mCEQ "Smoking Satisfaction" subscale measured at D4. |
|
E.5.2 | Secondary end point(s) |
• mCEQ "Smoking Satisfaction" (items 1, 2, and 12) subscale measured at D7, D14, D21 and D28 • mCEQ "Psychological Reward" (items 4 through 8); "Aversion" (items 9 and 10); "Enjoyment of Respiratory Tract Sensations" (item 3); and "Craving Reduction“ (item 11) subcales, measured at D4, D7, D14, D21 and D28 • Question “Have you found your urges to smoke stronger or weaker than usual in the last 24 hours?” (with response options of “much stronger,” “slightly stronger,” “same as before,” “slightly weaker,” and “much weaker”) at D4, D7, D14, D21 and D28 • Question “Have you found cigarettes more or less enjoyable than usual in the last 24 hours?” (with response options of “much more enjoyable,” “slightly more enjoyable,” “same as before,” “slightly less enjoyable,” and “much less enjoyable”) at D4, D7, D14, D21 and D28 • Change in MTSS from screening to D28 • Change in number of cigarettes smoked from screening to D28 • Preference question at EOS visit: “Is there one of the two administrations that made you want to quit smoking or reduce your cigarette consumption more than the other?”
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.5.1 | Number of sites anticipated in the EEA | 1 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Last visit of the last subject. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 12 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |